UK markets closed

Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
76.61-0.62 (-0.80%)
At close: 4:02PM EDT
Sign in to post a message.
  • R
    Real Immunotrader 10
    “Pharmacodynamic / unique synergy” what Dr Weber, the original Keytruda Investigator with the NCI for 8 years said about the $sls $mrk Preliminary data last year. Two checkpoint combination readouts now due. Dd on checkpoints - now add a massive proliferation of T Cells CD 3,4,8 targeted on Wt1 cancer cells: Cancer cells release into the bloodstream small vesicles armed with PD-1 ligand (PD-L1) — a protein that suppresses the activation of cancer-fighting immune cells — so as to mute anti-tumor immunity throughout the body, researchers report.
    Study results also showed that vesicle-associated PD-L1 in the blood may work as a treatment response biomarker, helping to distinguish patients most likely respond to anti-PD-L1 therapies.
    The study, “Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response,” was published in the journal Nature.
    A well-known and powerful mechanism of immune evasion by cancer cells is the presence of PD-L1 on their cell surface, which will bind to its PD-1 receptor on T-cells to prevent the activation of T-cells — a type of white blood cell that fights cancer.
    Previous studies have also shown that the presence of PD-L1 on cancer cells’ surface can increase in response to the release of interferon gamma (IFN-γ) — a protein with anti-cancer properties — by activated T-cells.
    Several approved anti-cancer therapies target and block this interaction (PD-L1 with its PD-1 receptor) to promote T-cell activation and stimulate anti-canter immune responses. However, many patients with PD-L1-producing cancers do not respond to these therapies.
    A collaboration between researchers — those at the University of Pennsylvania, Wuhan University, Xi’an Jiaotong University, Wistar Institute, University of Texas, and Mayo Clinic — sheds light on the immune-evasion mechanisms of cancer and possible causes behind the non-response to therapies.
  • R
    Real Immunotrader 10
    Pharmacodynamic / unique synergy” what Dr Weber, the original Keytruda Investigator with the NCI for 8 years said about the $sls $mrk Preliminary data last year. Two checkpoint combination readouts now due. Dd on checkpoints - now add a massive proliferation of T Cells CD 3,4,8 targeted on Wt1 cancer cells: Cancer cells release into the bloodstream small vesicles armed with PD-1 ligand (PD-L1) — a protein that suppresses the activation of cancer-fighting immune cells — so as to mute anti-tumor immunity throughout the body, researchers report.
    Study results also showed that vesicle-associated PD-L1 in the blood may work as a treatment response biomarker, helping to distinguish patients most likely respond to anti-PD-L1 therapies.
    The study, “Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response,” was published in the journal Nature.
    A well-known and powerful mechanism of immune evasion by cancer cells is the presence of PD-L1 on their cell surface, which will bind to its PD-1 receptor on T-cells to prevent the activation of T-cells — a type of white blood cell that fights cancer.
    Previous studies have also shown that the presence of PD-L1 on cancer cells’ surface can increase in response to the release of interferon gamma (IFN-γ) — a protein with anti-cancer properties — by activated T-cells.
    Several approved anti-cancer therapies target and block this interaction (PD-L1 with its PD-1 receptor) to promote T-cell activation and stimulate anti-canter immune responses. However, many patients with PD-L1-producing cancers do not respond to these therapies.
    A collaboration between researchers — those at the University of Pennsylvania, Wuhan University, Xi’an Jiaotong University, Wistar Institute, University of Texas, and Mayo Clinic — sheds light on the immune-evasion mechanisms of cancer and possible causes behind the non-response to therapies.
  • S
    Steve
    I still cannot find the percentage for adjusting my MRK cost basis and identifying the new OGN basis. Has anyone seen it yet?
    Also, any recent news about an OGN dividend in the future?
    Thanks, in advance, for any help.
  • a
    al
    Low for Friday is $15.32…did MRK stock hit that? No. But these things don’t happen by “error”. Obviously, Wall Street is manipulating the chart, and is resetting the technicals of this stock to suit its agenda. What that agenda is only time will tell, but I suspect it’s nothing good.
  • j
    john
    Merck continues to be one of history's most prolific and innovative drug companies. It's pipeline is strong esp. in oncology and infectious diseases. Their COVID drug is lookin good, but just a small part. And their dividend is solid. BUY!
  • g
    greg
    From the CEO Last week - The $MRK COMBO DATA IS SPECTACULAR - baby bio about to grow up about to be a billion dollar co.
    ‘There seems to be true and strong pharmacodynamic and - biological synergy between our lead asset, galinpepimut-S (GPS) and checkpoint inhibitor drugs. We are very pleased that we received notice of allowance of our patent application for this combination approach - could aim up to 20 indications and we look forward to providing further data from our study of GPS in combination with pembrolizumab in patients with 2nd or 3rd line relapsed/refractory metastatic ovarian cancer, as well as the study of GPS in combination with nivolumab in relapsed/refractory MPM later this quarter. The patent application is expected to be granted on June 15, 2021, as U.S. Patent No. 11,033,613. Really great work by our legal and clinical folks further strengthening our IP portfolio.
  • M
    Mike3333
    Analysts say that the one year target price is $93. I don't understand this, it should be at least $80 now.
    I bought 300 shares at $74, should I sell or add more around $70.
  • A
    Allen
    Been buying MRK in small amounts for my grand daughter via DSPP and DRIP. Have 17.6 shares which means she will now get 1 share of Organon and a little cash. What can I do with one share of Organon?
  • J
    John
    MRK have tested the therapeutic treatment on only 1,500 patients! They need to do 10 times this off to prove if it works.
  • A
    Anonymous
    With this down trend, something is wrong with Merck. Without insider stories, look at technical chart. It shows the stock is testing low again, next level at $71.5, then next at $69.5. Not pretty.
  • A
    Anonymous
    The excitement of spinoff is over. Did shareholders gain? No. Does the company operate more efficiently without this unit? I did not see it. Management needs to focus on efficiency, rather than playing games in financial number.
  • R
    Rob_Chemist
    Cost basis adjustment after the spin-off. For those who held MRK shares before the OGN spin-off, the new cost basis is as follows (based on TD Ameritrade). The cost basis of the MRK shares is reduced by 5%. The cost basis for the OGN shares is 5% of the price you paid for the MRK shares times 10. So, if you hold some MRK shares you bought at $80 prior to the spin-off, your new cost basis for MRK is $76 per share while the cost basis for OGN is $40 per share. I hope that this helps.
  • B
    Bjarne
    Let me guess, pharma is on a roll due to inflation fears? :-)
  • B
    Brent
    The "stops the replication of the disease" part to the news is huge, and the gov't by procuring $1.2 billion is certification of likely approval. MRK could find itself on the top of Covid medicines. Buy.
  • T
    The Chewdog
    16 days left, and counting until he’s GONE
  • J
    John
    Could break $80 this week???
  • g
    greg
    Analysts enjoyed having Thursdays commentary - easier in print, you can see the ceo told everyone the $mrk Keytruda data is worth billions.
  • M
    MAI
    I had Merck shares bought on May 27th, can I receive Oganon shares? I spoke to RBC direct investing, they said I have to call Merck to figure out about this. Can some one advise how can I get cost adjustment from Merck as I have 600 shares as of today? Many thanks
  • J
    John
    MRK struck $1.2B COVID-19 deal which is awesome. $80-$85 is coming!
  • H
    Howie
    let's just remind folks that you shouldn't believe all you read on a message board. Go to the source of the information for solid answers